United Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UTHR research report →
About the company
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity.
- CEO
- Martine A. Rothblatt
- IPO
- 1999
- Employees
- 1,305
- HQ
- Silver Spring, MD, US
Price Chart
- Market Cap
- $23.60B
- P/E
- 18.99
- P/S
- 7.44
- P/B
- 4.10
- EV/EBITDA
- 13.14
- Div Yield
- 0.00%
- Gross Margin
- 86.58%
- Op Margin
- 45.34%
- Net Margin
- 40.61%
- ROE
- 19.24%
- ROIC
- 18.81%
- Revenue
- $3.18B · 10.61%
- Net Income
- $1.33B · 11.68%
- EPS
- $30.13 · 13.96%
- Op Income
- $1.52B
- FCF YoY
- -3.69%
- 52W High
- $609.35
- 52W Low
- $272.12
- 50D MA
- $559.65
- 200D MA
- $504.11
- Beta
- 0.57
- Avg Volume
- 501.16K
Get TickerSpark's AI analysis on UTHR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | ROTHBLATT MARTINE A | other | 9,500 |
| Jul 2, 26 | ROTHBLATT MARTINE A | other | 9,500 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 192 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 130 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 118 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 640 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 993 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 776 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 2,006 |
| Jul 2, 26 | ROTHBLATT MARTINE A | sell | 2,942 |
Our UTHR coverage
Recent articles, reports, and earnings notes.
Should You Buy the Vicore Pharma Holding AB IPO? Here's the Setup
Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.
Incyte is getting sold like a one-drug story even as the second act gets closer
Incyte is still being traded like Jakafi is the whole story, and that framing is getting stale. Revenue grew 21% in Q1, Jakafi XR is already approved, and a September FDA catalyst gives the pipeline a much more investable shape than the stock seems to reflect.
Want a deeper read on UTHR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.